Alex Aylen's questions to Pacific Biosciences of California Inc (PACB) leadership • Q1 2025
Question
Alex Aylen from Canaccord Genuity questioned the key factors behind pausing the high-throughput short-read sequencer development and asked about any observed cannibalization of Revio by Vega.
Answer
Christian Henry, President and CEO, explained the decision was driven by the macroeconomic environment, the need to focus resources on the competitively stronger long-read market, and rapid R&D progress on the long-read side. On the second point, Henry stated they are not seeing direct cannibalization, but rather customers opting for the more affordable Vega due to current funding constraints, with the expectation they will adopt Revio later. He noted that about 50% of Vega customers are new to PacBio.